<DOC>
	<DOCNO>NCT02132169</DOCNO>
	<brief_summary>The purpose study evaluate safety AC-170 0.24 % use twice daily Healthy Adult Subjects Pediatric subject history family history atopic disease ( include allergic conjunctivitis ) .</brief_summary>
	<brief_title>A Multi-Center Study Evaluating Safety AC-170 0.24 %</brief_title>
	<detailed_description />
	<mesh_term>Conjunctivitis</mesh_term>
	<mesh_term>Conjunctivitis , Allergic</mesh_term>
	<mesh_term>Cetirizine</mesh_term>
	<criteria>least 2 year age able selfadminister eye drop parent/legal guardian available purpose le 18 year old history family history atopic disease ( include allergic conjunctivitis ) ocular health within normal limit know contraindication sensitivity study medication component ocular condition , opinion investigator , could affect subject safety trial parameter use disallowed medication period indicate prior enrollment study</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>